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Abstract. Artemisinin-based combination therapies (ACTs) are the first-line treatment of uncomplicated malaria.
The public health benefit and safety of repeated administration of a given ACT are poorly studied. We conducted a
randomized trial comparing artemether-lumefantrine, artesunate plus amodiaquine (AS+AQ) and artesunate plus
sulfadoxine-pyrimethamine (AS+SP) in patients 6 months of age and older with uncomplicated malaria in Mali from
July 2005 to July 2007. The patient received the same initial treatment of each subsequent uncomplicated malaria
episode except for treatment failures where quinine was used. Overall, 780 patients were included. Patients in the
AS+AQ and AS+SP arms had significantly less risk of having malaria episodes; risk ratio (RR) = 0.84 (P = 0.002) and
RR = 0.80 (P = 0.001), respectively. The treatment efficacy was similar and above 95% in all arms. Although all drugs
were highly efficacious and well tolerated, AS+AQ and AS+SP were associated with less episodes of malaria.
INTRODUCTION
According to the World health Organization (WHO) 2010
report, in the 106 malaria-endemic countries, 225 million
cases of malaria led to an estimate of 781,000 deaths in 2009.1
Once a person develops malaria, the only means of reducing
suffering and preventing death is by diagnosing and treating
the disease.2 To counter the threat of resistance of Plasmodium
falciparum to monotherapies, and to improve treatment out-
come, WHO recommends that artemisinin-based combination
therapies (ACTs) be used for the treatment of uncomplicated
P. falciparummalaria.2
The choice of the ACTs in sub-Saharan African countries
was mostly based on the efficacy and safety data of a single
malaria episode treatment that does not take into account the
long-term impact on malaria incidence and safety, which may
have a given ACT when used over and over to treat consecu-
tive malaria episodes.
In addition, as the first generation ACTs are being rolled
out, studies show that they may rapidly increase the preva-
lence of molecular markers associated with resistance to the
partner drugs, i.e., lumefantrine, amodiaquine, or sulfadoxine-
pyrimethamine.3–7
Although data are available for the use of ACTs during
single-episode treatment,8–12 there are limited data on safety
and public health benefits in terms of overall incidence of
clinical episodes during the use of the same ACT during
repeated malaria episodes treatment.13–17
To address these gaps this study aimed to evaluate the
public health impact in terms of incidence of clinical episodes
and the efficacy and safety of artemether-lumefantrine (AL),
artesunate plus amodiaquine (AS+AQ), and artesunate plus
sulfadoxine-pyrimethamine (AS+SP) when used repeatedly
for consecutive clinical malaria episodes during as long as
24 months.
MATERIALS ANDMETHODS
Study site. The study was conducted from July 2005 to
July 2007 in Bougoula-Hameau, a peri-urban village of 5,000
inhabitants located in the South ofMali. Plasmodium falciparum
is hyperendemic with seasonal peaks that occur during the rainy
season (June–November).
Study design and procedures. This was an open-label, ran-
domized clinical trial comparing three different ACTs: AL,
AS+AQ, and AS+SP.
When malaria was suspected finger-prick blood was taken
for thick blood films. After ensuring that inclusion criteria
are met, a written informed consent was obtained. Patients
were included if they were at least 6 months of age, weighed
³ 5 kg, resided in the study village, were able to receive oral
treatment, had an axillary temperature ³ 37.5°C, and had
Plasmodium sp. infection with a parasite density between
2,000 and 200,000 asexual forms per microliter of blood for
the first episode. The first subject was enrolled in July 2005
and the enrollment completed with the last subject enrolled
30 October 2006, although the last malaria episode follow-up
ended in July 2007. Subjects with the following characteris-
tics were not included in the study: the presence of severe or
complicated malaria18; a severe concomitant pathology or
one that needed a medical follow-up incompatible with the
study, an allergy to one of the drugs involved in this study,
and a pregnancy.
Eligible subjects were randomized to receive either AL or
AS+AQ or AS+SP, and followed up for 28 days after the
treatment initiation with one of the three ACTs, according
to the 2003 WHO19 treatment assessment guideline. Block-
randomization was used to allocate the patients to the three
treatment arms. Treatment assignments were through sequen-
tially numbered opaque envelops that concealed the actual
treatment to which the patient was randomized.
Once subjects were assigned to a given group, in the event
of subsequent uncomplicated malaria episodes defined as
the presence of malaria signs or symptoms plus Plasmodium
sp. infection (a positive blood smear with parasite density
< 200,000 parasites/mL), they were re-treated with that same
treatment regimen (except in case of parasite recurrence
cases occurring within each 28-day treatment follow-up
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period where quinine was used). Patients were closely fol-
lowed both clinically and biologically to record any adverse
event. Patients with > 200,000 parasites/mL or who had treat-
ment failure during the 28-day follow-up period or who
developed severe malaria were treated with quinine and/or
hospitalized if necessary. The study team was present
24 hours a day, 7 days a week at the study site during the
study period.
Enrolled patients were asked to return for clinical and/or
biological follow-up on Days 1, 2, 3, 7, 14, 21, 28, or on days of
recurrent illness. Patients or guardians were asked about any
medicine consumption outside the research facility since the
last clinic visit. At each visit, a physical examination, including
axillary temperature, was performed and blood was taken for
thick smears. Patients were asked to return to the clinic any
time if they became ill.
Thick blood films and blood onto filter paper samples were
made on Days 0, 2, 3, 7, 14, 21, 28, and on any days of recur-
rent illness. Parasitemia were measured by counting the num-
ber of asexual parasites against 300 leukocytes on the thick
blood film, and then reported to a microliter of blood based
on a count of 7,500 leukocytes/mL.20 If gametocytes were
seen, a gametocyte count was performed against 1,000 leuko-
cytes. Although this was an open-label study, all malaria
slides were read in a blinded fashion by the technicians,
because the parasitological result was the key element in the
determination of the primary endpoint.
Blood blotted onto filter-paper samples were obtained for
molecular analyses of drug resistance markers and to distin-
guish recrudescent from re-infections.
Hematology (hemogramme) and biochemistry (creatinemia
and alanine aminotransferase) analysis were performed on
Day 0, 7, and also on any other day if deemed clinically
necessary to assess the biological toxicity of the study drugs.
Normal values were based on laboratory parameters obtained
from Malian population (our unpublished data). The val-
ues outside the normal ranges were considered abnormal
and graded.
MSP1, MSP2, and CA1 polymorphisms were analyzed using
standard methods with polymerase chain reaction (PCR) to
discriminate true recrudescent parasites from new infections.7
Severe malaria cases and parasite recurrence cases occur-
ring within each 28-day treatment follow-up period were
treated with quinine (8 bmg/kg three times daily for 7 days)
and re-enrolled (after complete remission) for the subsequent
uncomplicated malaria (presence of malaria signs or symp-
toms plus Plasmodium sp. infection, which is defined as a pos-
itive blood smear with parasite density < 200, 000 parasites/mL)
with the same study treatment arm. Quinine was chosen
because it was the second-line drug for malaria treatment.
The efficacy data analysis was based on the WHO 2003,
28-day treatment efficacy assessment guideline19; the efficacy
was determined in each subject after an uncomplicated
malaria episode where the subject received the same ACT
as during the initial randomization study arm. Treatment
outcomes were classified as early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure (LPF),
and adequate clinical and parasitological response (ACPR).
All study medicines were administrated orally by desig-
nated study personnel at the health center. The AS+AQ was
Arsucam coblister (AS 50 mg/AQ 153 mg; Sanofi-Aventis,
Paris, France), given once daily for 3 days to the following
scheme: for patients < 10 kg, 1/2 tablet AS + 1/2 tablet AQ;
10–20 kg, 1 tablet AS+ 1 tablet AQ; 21–40 kg, 2 tablets AS+
2 tablets AQ; > 40 kg, 4 tablets AS+ 4 tablets AQ.
The AS+SP was Arsumax (AS 50 mg; Sanofi-Aventis, Paris,
France) + sulfadoxine–pyrimethamine (S _ 500 mg/P _ 25 mg,
Fansidar Roche, Burlington, NC), given once daily for 3 days
to the following scheme: for patients £ 10 kg, 1/2 tablet AS+ 1/2
tablet SP; 11–20 kg, 1 tablet AS+ 1 tablet SP; 21–40 kg, 2 tablets
AS+ 2 tablets SP; > 40 kg, 4 tablets AS+ 3 tablets SP. The SP
is given only the first day, whereas AS is given over 3 days.
The AL was Coartem (Novartis Pharma AG, Basel,
Switzerland), given twice daily for 3 days to the following
scheme: for patients < 15 kg, 1 tablet; 15–24 kg, 2 tablets;
25–34 kg, 3 tablets; ³ 35 kg, 4 tablets.
Ethics. The study protocol was reviewed and approved by
the Ethical Committee of the Faculty of Medicine, Pharmacy
and Dentistry, University of Bamako, Mali. Community per-
mission was obtained before the start of the study as described
by Diallo and others.21 Individual, written, informed consent
was obtained from each patient (if adult) or parent or guardian
of each child before enrolment.
Sample size. Calculation of sample size was based on the
assumptions that patients experienced an average of two
clinical episodes per person per year if treated by AL and
Figure 1. Study trial profile.
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living in the study areas and that treatment with AS+AQ or
AS+SP would reduce this value by 35%, which is 1.3 clini-
cal episodes per person per year. With an error risk alpha
set at 0.05, a power of 90%, 174 subjects were needed in
each arm. If one takes into account loss of follow-up and
data attrition, 260 subjects were needed in each arm (total
sample of 780).
Data management and statistical procedures. Data were
double entered and validated usingMicrosoftAccess (Microsoft,
Redmond, WA) and then analyzed using Stata software ver-
sion 10.0 (StataCorp., College Station, TX).
For univariate analysis, c2 or Fisher’s test if appropriate was
performed to compare categorical variables. Normally distrib-
uted continuous variables were compared with analysis of
variance. Nonparametric tests were used when appropriate.
Parasite recurrence occurring within each 28-day treatment
follow-up was counted as a new malaria episode because it
was associated with full malaria rescue treatment regimen.
However, following 14 days after each malaria rescue treat-
ment with quinine, the subject was not considered at risk of
malaria, therefore that time was deducted in the subject’s
total length of time. Negative binomial regression analysis
adjusted for repeated events for the same subject was used to
estimate relative risk between study drugs.
The incidence rate is defined as number of malaria episodes
in each study arm divided by the time length in days of each
participant (person-time) and then expressed in a year (by
dividing by 365.25 days).
Efficacy analysis concerned all combined malaria episodes
from each participant. An intention-to-treat (ITT) analysis
for drug efficacy was based on all subjects randomized to their
respective treatment arm.
A per-protocol (PP) analysis for drug efficacy was also per-
formed and excluded missing (lost to follow-up, withdrawal)
data and major protocol violation cases.
For safety data, all subjects who received at least one dose
starting from their first episode of malaria were included into
the safety analysis.
RESULTS
Study trial profile and baseline characteristics. The trial pro-
file is summarized in Figure 1. A total of 4,218 patients
attended the clinic with malaria symptoms, 780 subjects who
met the enrollment criteria were included in the study;
260 patients per treatment arm. A total of 2,463 malaria epi-
sodes were documented during the study, although 23 partici-
pants did not complete the study (Figure 1). The reasons for
not completing the study were: travel (2 in the AL arm, 4 in the
AS+AQ arm, and 3 in the AS+SP arm); consent withdrawal
(4 in the AL arm, 1 in the AS+AQ arm, and 1in the AS+SP
arm); treatment allocation errors that were not excluded from
the study but adjusted into the analysis (1 subject received
AS+AQ instead of AS+SP the original allocated treatment
arm, 1 subject received AS+SP instead of AS+AQ the origi-
nally allocated treatment arm, 1 subject received AS+SP for
the second episode instead of AL the originally allocated
treatment arm); 2 cases of death in AS+SP arm;1 case in the
AL arm received chloroquine treatment at home during the
first malaria episode treatment; 1 case in the AS+AQ arm
Table 1
Baseline characteristics per treatment group and overall at enrollment*
Characteristics
Regimen (AS+AQ)
(N = 260)
Regimen (AS+SP)
(N = 260)
Regimen (AL)
(N = 260) P value
Age (years)
Mean ± SD 5.37 ± 6.19 5.23 ± 4.1 5.94 ± 6.8 0.51
Median (min, max) 4.1 (0.5,68.6) 4.3(0.5,30.5) 4.3(0.5,46.6)
Age category n (%) 0.72
< 5 155 (59.6) 147 (56.5) 146 (56.2)
5–9 78 (30.0) 85 (32.69) 88 (33.9)
10–14 18 (6.9) 21 (8.1) 14 (5.4)
³ 15 9 (3.5) 7 (2.7) 12 (4.6)
Gender – n (%)
Female 142 (54.6) 129 (49.6) 130 (50.0) 0.45
P. falciparum (/mL)
Median (Q1,Q3) 21,550 (10,375, 45,150) 23,225 (9,990, 44,190) 21,925 (10,440, 42,050) 0.99
Gametocyte– n (%) 16 (6.2) 18 (6.9) 28 (10.8) 0.11
*n = frequency; Q1 = 25th percentile; Q3 = 75th percentile; Min =minimum; Max =maximum; AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; AS+SP = artesunate plus
sulfadoxine-pyrimethamine.
Table 2
Incidence rates and RR per treatment arm and per age (in year) category*
Factors Numbers of episodes (years at risk) Incidence rate (95% CI) Adjusted* RR (95% CI) P value
AL 923 (341.42) 2.70 (2.53–2.88) 1
AS+AQ 768 (340.59) 2.25 (2.12–2.44) 0.84 (0. 75–0.93) 0.001
AS+SP 756 (346.99) 2.18 (2.06–2.38) 0.80 (0.72–0.89) < 0.001
Age ³ 15 40 (41.07) 0.97 (0.70–1.33) 1
Age 10–14 108 (71.44) 1.51 (1.24–1.83) 1.59 (1.07–2.34) 0.020
Age 5–9 779 (337.49) 2.31 (2.15–2.48) 2.41 (1.72–3.38) < 0.001
Age < 5 1520 (579.0) 2.63 (2.49–2.76) 2.74 (1.96–3.82) < 0.001
*Adjusted for age.
RR = risk ratio; AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; S+SP = artesunate plus sulfadoxine-pyrimethamine; CI = confidence interval.
52 SAGARA AND OTHERS
received quinine treatment at home during the second malaria
episode treatment; and 1 case in the AS+AQ arm developed
severe anemia during its first malaria episode treatment that
required blood transfusion at the hospital.
At enrollment (Table 1), the mean age, sex ratio, the
median parasitemia of P. falciparum, and the prevalence of
gametocyte carriage were all similar in all three treatment
arms. Only two cases of Plasmodium ovale and no case of
Plasmodium malariae monospecific infection was detected,
whereas 8% (N = 780) of P. falciparum + P. malariae and
0.8% (N = 780) of P. falciparum + P. ovale mixed infection
were found (data not shown).
ACT and malaria incidence rate. Table 2 shows that the
malaria incidence rate per person and per year was 2.70
(95% confidence interval [CI]: 2.53–2.88), 2.25 (95% CI:
2.12–2.44), and 2.18 (95% CI: 2.06–2.38) respectively in AL,
AS+AQ, and AS+SP arms.
In multivariate modeling (Table 2), patients in the AS+AQ
and AS+SP arms had significantly less risk of having malaria
episodes than patients in the AL arm; risk ratio [RR] = 0.84
(P = 0.002) and RR = 0.80 (P = 0.001), respectively. There-
fore, compared with AL the risk of malaria incidence reduc-
tion was 16% and 20% for AS+AQ and AS+SP, respectively.
Using the age group ³ 15 years of age as reference (Table 2),
patients in the age group 10–14 years, the age group 5–9 years,
and the age group < 5 years had significantly more risk of
having malaria episodes; RR = 1.60 (P = 0.002), RR = 2.44
(P = 0.001), and RR = 2.76 (P = 0.001), respectively.
ACT efficacy on uncomplicated malaria.Non-PCR-corrected
ACPR was significantly different between the study arms
(62.0% (N = 665), 78.5% (N = 619), and 89.1% (N = 678) in
AL, AS+AQ, and AS+SP arms, respectively, P < 0.001).
Figure 2 shows that there was a significant difference in the
non-PCR-corrected ACPRs between the treatment arms
according to the season. The lowest ACPRs were docu-
mented during rainy seasons when malaria transmission is
highest (July–September followed by October–December).
This seasonal variation in the efficacy of ACTs was docu-
mented for two consecutive years.
Using the ITT analysis (Table 3), the PCR-corrected
ACPR were high and similar for all study arms 94.4%,
95.8%, and 97.9% in the AL, AS+AQ, and AS+SP arm,
respectively. The difference of efficacy between any two arms
treatment is < 5%.
Using the PP analysis (Table 3), the PCR-corrected ACPR
were also high for all study arms; 99.1%, 98.7%, and 99.6%
respectively in the AL, AS+AQ, and AS+SP arm.
Safety and tolerability. The adverse events with the highest
incidence was mild vomiting, which was higher in AS+AQ and
AS+SP than in the AL arm (P < 0.001), followed by abdomi-
nal pain and headaches (Table 4), which was similar in the
three arms. One subject who had vomiting in the AS+AQ arm
discontinued the oral treatment and parenteral quinine was
provided because of the repeated drug dose vomiting. The
frequency of the other adverse events was similar in the three
arms. The incidence of laboratory adverse events was similar
in the three treatments arms except for the creatinemia which
significantly different; 5.09%, 6.33% and 15.19% in the AL,
AS+AQ, and AS+SP arm respectively, P < 0.001.
Serious adverse events (SAEs) were documented and
included 2 severe cases of anemia (1 in AL arm, 1 in AS+AQ
arm); 2 cases of seizure (1 in AL arm, 1 in AS+AQ arm); 1 case
of severe malaria (in AL arm); 1 case of coma caused by
hypoglycemia (in AS+SP); 1 case of presumed pneumopathy
Figure 2. Per protocol non-polymerase chain reaction (PCR)
corrected adequate clinical and parasitological responses (ACPRs)
per study arm, per season, and per year. Non-PCR corrected
ACPRs per study arm, per season, and per year. The numbers of
patients (n/N) with non-corrected ACPRs were 51/105, 82/105, and
90/107, respectively, for AL, AS+AQ, and AS+SP in July–September
2005, 68/120, 87/107, and 114/121 in October–December 2005; 29/29,
25/25, and 22/22 in January–March 2006; 31/43, 33/45, and 47/53 in
April–June 2006; 115/188, 127/176, and 163/191 in July–September
2006; 75/126, 94/119, and 140/150 in October–December 2006; 32/33,
24/24, and 16/16 in January–March 2007; 11/13, 13/13, and 12/12 in
April–June 2007.
Table 3
Efficacy evaluation on Day 28 after PCR correction* ITT and PP analysis
AL (N = 665) AS+AQ (N = 619) AS+SP (N = 678) P value
Possible failure* – n (%) 31 (4.7) 18 (2.9) 11 (1.6) 0.005
ETF† – n (%) 0 (0) 1 (0.2) 0 (0) 0.32
LCF† – n (%) 2 (0.3) 1 (0.2) 0 (0) 0.43
LPF† – n (%) 4 (0.6) 6 (1.0) 3 (0.4) 0.5
ITT–ACPR – n (%) 628 (94.4) 593 (95.8) 664 (97.9) 0.004
PP–ACPR – n/N (%) 628/634 (99.1) 593/601 (98.7) 664/667 (99.6) 0.25
Reinfection rate – n/N (%) 231/634 (36.4) 117/601 (19.5) 62/667 (9.3) < 0.001
*Possible failure: lost to follow-up or withdrawal or subjects for which filters were missing or undetermined PCR.
†These are computed according to ITT analysis.
PCR = polymerase chain reaction; ITT = intention-to-treat; PP = per protocol; AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; AS+SP = artesunate plus sulfadoxine-
pyrimethamine; n/N = frequency; ETF = early treatment failure; LCF = late clinical failure; LPF = late parasitological failure; ACPR = adequate clinical and parasitological failure.
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(in AS+SP arm); 2 cases of death in AS+SP arm (one caused
by pneumonia and the other to hypoglycemia). The occur-
rence of SAE was comparable in the three arms. All of the
above non-fatal SAE resolved without sequelae. The two
cases of death happened in the AS+SP arm, although a causal
relationship with the study product was not established. All
SAEs were assessed as not related to the study drugs. There
was no significant laboratory abnormalities (hemogramme,
creatinemia, and alanine aminotransferase parameters) related
to any of the study treatment drugs (Table 4).
DISCUSSION
Over 24 months of follow-up of this study show that the
incidence of uncomplicated malaria was significantly lower in
the AS+SP and AS+AQ arms than in the AL arm. This could
be explained by the lowest re-infection rate seen in the
AS+SP and AS+AQ arms and maybe because of the longer
half life of the partner drugs7 (AQ or SP) or else to increasing
resistance to lumefantrine. However, in vitro studies con-
ducted during the same period in Mali did not show any
lumefantrine resistance.22
Our results are in contrast with the result of a study
conducted in Ghanaian children15 with repeated treatment of
AS+AQ or AL where a similar incidence rate between the
two study arms was reported. This may be because in our
study, we counted late parasitological failures caused by
re-infections (as determined by PCR) as new malaria epi-
sodes. As in our study, the author reported good safety profile
and high 28-day follow-up treatment efficacy in both arms
(AS+AQ and AL). We found that malaria incidence was high
in children < 5 years of age but also in children > 5 years of age
compared with adults.
The high PCR-corrected 28-day follow-up treatment effi-
cacy results are consistent with reports from the same area in
2004 where ACPRs rates of 100% and 99.1% were found with
AS+SP and AS+AQ, respectively.7 Our data are similar to
those of Senegal17 and Indonesia with AS+SP23 and a multi-
center study in Africa with AL and AS+AQ.24
The re-infection rate was higher in the AL arm as com-
pared with AS+AQ and AS+SP arms (P < 0.001). This high
reinfection rate with AL is in contrast with studies in
Uganda25 and Tanzania13 where lower reinfection rates
were reported in AL compared with AS+AQ. The authors
thought that the higher reinfection rates in AS+AQ could be
explained by the relatively high amodiaquine resistance level
in the study area. This study found that the risk of recurrent
parasitemia (uncorrected PCR 28-day follow-up ACPR)
malaria had a significant seasonal variation. We found signif-
icant recurrent parasitemia during the rainy season compared
with the dry season. This study finding is consistent with a
Ugandan study,25 which also found significant seasonal vari-
ation in recurrent parasitemia despite the perennial malaria
transmission pattern in that study setting. The significant
recurrent parasitemia during the rainy season compared with
the dry season could be explained by the high intensity of the
malaria transmission during the rainy season compared with
the dry season.
Our participants received quinine as a second-line treat-
ment. However, it is unclear whether quinine, the same
ACT, or a different ACT would be the optimal treatment.
Given that nearly all recurrent parasitemia were caused by
new infections, it might have been reasonable to retreat with
the same ACT regimen, rather than with quinine.
The repeated treatment using the same ACT in this study
showed a good safety profile. This finding is consistent with
other studies that also reported a good safety profile of
repeated treatment of ACT,13–15,17 even in chronically mal-
nourished children with or without HIV infection.14 Although
AL was associated with a higher reinfection rate and hence
higher malaria incidence rate, it did produce fewer side effects
such as vomiting.
Limitations of this study include the consideration of
asymptomatic parasite carriers from Day 7 during each 28-day
treatment follow-up as treatment failures (as in the WHO
treatment assessment guidelines19), which were treated with
quinine and counted as malaria episodes for new infections as
determined by PCR. The overall malaria episodes may be
similar if one considered only symptomatic parasite recur-
rence during each 28-day treatment follow-up and the clinical
episodes occurring afterward. Although our sample size cal-
culation assumptions expected differences equal or greater
than 35%, we observed statistically significant differences in
malaria incidence reduction of 16% and 20% with AS+AQ
and AS+SP, respectively, compared with AL. This is probably
because our original calculation was conservative and yielded
a rather large sample size, resulting in smaller differences
being statistically significant. In addition, the mean malaria
incidence was higher than expected (two episodes expected
but almost three episodes observed)
We show that ACTs that had very high and similar efficacy
and safety by the standard 28-day drug efficacy test could
have a different impact on malaria incidence over a longer
period. In this era of high efficacy of ACTs, the choice of a
first-line treatment policy should go beyond short-term effi-
cacy and safety to include longer follow-ups and repetitive
treatments with the same regimen. Additional studies will be
Table 5
Incidence of laboratory adverse events* occurred within 28 days
after treatment initiation
Laboratory
adverse events AL n/N (%) AS+AQ n/N (%) AS+SP n/N (%) P value
ALAT 4/568 (0.72) 4/537 (0.74) 7/592 (1.18) 0.68
Creatinemia 27/530 (5.09) 31/490 (6.33) 84/553 (15.19) < 0.001
Leucopenia 2/578 (0.35) 1/551 (0.18) 5/600 (0.83) 0.30
*Laboratory values normal on Day 0 but abnormal during follow-up. All incident cases
of leucopenia were grade 1 (mild; < 3,500–2,500 leukocytes mm3).
AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; AS+SP = artesunate
plus sulfadoxine-pyrimethamine; ALAT = alanine aminotransferase; n/N = frequency.
Table 4
Incidence of adverse events* occurred within 3 days after treatment
initiation
Symptoms/signs AL n/N (%) AS+AQ n/N (%) AS+SP n/N (%) P value
Vomiting 25/281 (8.9) 58/269 (21.6) 67/289 (23.2) < 0.001
Headaches 2/30 (6.7) 7/39 (18.0) 5/49 (10.2) 0.36
Asthenia 0/113 1†/123 (0.81) 0/135 0.64
Dizziness 0/129 2/132 (1.5) 1/146 (0.7) 0.53
Anorexia 0/109 3/123 (2.4) 2/140 (1.4) 0.33
Abdominal pain 8/100 (8.0) 8/85 (9.4) 9/104 (8.7) 0.94
Rash 1/654 (0.15) 0/612 0/666 0.65
*These adverse events are considered to be related to the study drugs because of the
temporal relationship with the study drug although the possibility that these symptoms can
also be caused by malaria.
†The subject was having difficulty walking during the asthenia episode.
AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; AS+SP =
artesunate plus sulfadoxine-pyrimethamine; n/N = frequency.
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required to assess the overall impact of the large-scale deploy-
ment of ACTs on malaria in the field.
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